Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).

4142Background: KRAS mutations (m) (KRASm) are present in over 90% of pancreatic adenocarcinomas (PDAC) with a predominance of G12 substitutions. KRAS wildtype (WT) PDAC relies on alternate oncogen...